Literature DB >> 12708480

Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies.

Shin-ichi Nakatsuka1, Tetsuya Takakuwa, Yasuhiko Tomita, Yoshihiko Hoshida, Mieko Nishiu, Motoko Yamaguchi, Kazuhiro Nishii, Woo-Ick Yang, Katsuyuki Aozasa.   

Abstract

Death-associated protein (DAP) kinase is a pro-apoptotic serine/threonine kinase with a death domain, which is involved in apoptosis induced by interferon-gamma, tumor necrosis factor-alpha, and Fas ligand. Down-regulation of DAP kinase gene expression by hypermethylation of its promoter region might result in resistance to apoptotic cell death, and could provide a basis for tumor development. In the present study, we employed methylation-specific polymerase chain reaction to examine the methylation status of CpG islands in the DAP kinase gene in 19 cases of T-cell malignancies (including eight adult T-cell leukemia/lymphoma), 24 of natural killer (NK)/T-cell, and 34 of B-cell. Frequency of methylation was significantly higher in B-cell (27 of 34, 79.4%) than in T-cell malignancies (nine of 19, 47.4%) (P<0.05). Fifteen of 24 (62.5%) NK/T-cell lymphomas showed DNA methylation. One B-cell lymphoma cell line with DNA methylation was resistant to apoptotic stimuli, and treatment of the cells with a demethylating agent restored apoptotic cell death. These findings suggested that suppression of DAP kinase expression by DNA methylation might play a substantial role in the development of not only B-cell, but also T- and NK/T-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12708480     DOI: 10.1111/j.1349-7006.2003.tb01357.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  8 in total

1.  Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.

Authors:  Kristie A Blum; Zhongfa Liu; David M Lucas; Ping Chen; Zhiliang Xie; Robert Baiocchi; Donald M Benson; Steven M Devine; Jeffrey Jones; Leslie Andritsos; Joseph Flynn; Christoph Plass; Guido Marcucci; Kenneth K Chan; Michael R Grever; John C Byrd
Journal:  Br J Haematol       Date:  2010-04-29       Impact factor: 6.998

2.  An inducible caspase 9 safety switch for T-cell therapy.

Authors:  Karin C Straathof; Martin A Pulè; Patricia Yotnda; Gianpietro Dotti; Elio F Vanin; Malcolm K Brenner; Helen E Heslop; David M Spencer; Cliona M Rooney
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

Review 3.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

4.  Risk Factors of Follicular Lymphoma.

Authors:  Shuangge Ma
Journal:  Expert Opin Med Diagn       Date:  2012-05-08

Review 5.  Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review.

Authors:  John Hayslip; Alberto Montero
Journal:  Mol Cancer       Date:  2006-10-06       Impact factor: 27.401

6.  EPMA position paper in cancer: current overview and future perspectives.

Authors:  Godfrey Grech; Xianquan Zhan; Byong Chul Yoo; Rostyslav Bubnov; Suzanne Hagan; Romano Danesi; Giorgio Vittadini; Dominic M Desiderio
Journal:  EPMA J       Date:  2015-04-15       Impact factor: 6.543

Review 7.  The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis.

Authors:  Danjie Jiang; Qingxiao Hong; Yusheng Shen; Yan Xu; Huangkai Zhu; Yirun Li; Chunjing Xu; Guifang Ouyang; Shiwei Duan
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

8.  Exploration of molecular features of PCOS with different androgen levels and immune-related prognostic biomarkers associated with implantation failure.

Authors:  Qinyu Gao; Cong Ma; Shuyu Meng; Guanxiong Wang; Qiong Xing; Yuping Xu; Xiaojin He; Tianjuan Wang; Yunxia Cao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.